Crossmark

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance

Crossref DOI link: https://doi.org/10.1038/s41391-018-0101-6

Published Online: 2018-12-12

Published Print: 2019-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kim, Hyung L.

Li, Ping

Huang, Huei-Chung

Deheshi, Samineh

Marti, Tara https://orcid.org/0000-0002-6362-5775
Knudsen, Beatrice

Abou-Ouf, Hatem

Alam, Ridwan https://orcid.org/0000-0001-7805-9596
Lotan, Tamara L.

Lam, Lucia L. C.

du Plessis, Marguerite

Davicioni, Elai

Fleshner, Neil

Lane, Brian R.

Ross, Ashley E.

Davis, John W.

Mohler, James L.

Trock, Bruce J.

Klein, Eric A. https://orcid.org/0000-0002-1783-0698
Tosoian, Jeffrey J.

Hyndman, M. Eric

Bismar, Tarek A.
License Information

Text and Data Mining valid from 2018-12-12
More Information

Article History

Received: 14 June 2018

Revised: 28 August 2018

Accepted: 31 August 2018

First Online: 12 December 2018

Compliance with ethical standards

:

: HLK is the co-founder of Oncotherapies. H-CH, SD, TM, LLCL, MdP, and ED are employees of GenomeDx Biosciences.